SHARx, LLC.

10/16/2026

'𝐎𝐧 𝐭𝐡𝐞 𝐑𝐚𝐝𝐚𝐫' | 32nd Edition is live!

PBM reform is gaining momentum, but will greater transparency actually lead to lower pharmacy costs?

In this edition, we cover
• Why bigger PBM rebates aren't translating into lower employer drug spend
• The Big Three PBMs losing ground as employers explore alternatives
• New challenges threatening access to affordable prescription imports
• Drug launch prices reaching new highs
• Growing pressure on employers from hospital and pharmaceutical pricing
• The ongoing debate over prior authorization and medication access

Transparency is only part of the solution. Employers need to look beyond rebates and pricing models to understand total pharmacy spend, clinical value, and the true financial impact on their plans.

Check out the thirty-second edition: 🔗 https://sharxplan.com/on-the-radar-32nd-edition/

10/02/2026

Employers are increasingly stepping up as healthcare purchasers, and trusting the old plan model is no longer enough. To control rising costs and hidden fees, leaders must demand full visibility into their spending.

As Paul Pruitt, co-founder and CGO at SHARx, notes: “Transparency should no longer be viewed as a luxury; it should be an expectation. Employers cannot effectively manage any major business expense if they cannot see the underlying data.”

Read the full article to learn how to evaluate your organization's healthcare strategy and uncover hidden costs: 🔗 https://sharxplan.com/news/whos-really-managing-your-healthcare-dollars/

10/02/2026

'𝐎𝐧 𝐭𝐡𝐞 𝐑𝐚𝐝𝐚𝐫' | 31st Edition is live!

Healthcare costs are rising, but the bigger challenge is understanding what’s actually driving them.

This edition covers:
• Why unclear prescription prices are affecting patient behavior
• New tools for evaluating PBM contracts and fiduciary protections
• Why employers are moving beyond traditional cost-shifting
• Pharmacy benefits becoming a bigger C-suite priority
• The expanding role of brokers in healthcare cost management

Managing pharmacy spend requires looking beyond the price tag to contracts, competition, utilization, patient access, and fiduciary oversight.

Check out the thirty-first edition: 🔗 https://sharxplan.com/on-the-radar-31st-edition/

09/23/2026

While national policy discussions focus on Most-Favored-Nation drug pricing deals, simply lowering manufacturer costs does not automatically translate to relief at the pharmacy counter.

"All of Pharma seems to have these long-term contractual agreements with the government programs and the commercial markets, and they're all intertwined and interconnected in a very challenging way that is not easy to unwind," explained SHARx Chief Growth Officer Paul Pruitt.

Read the article to explore the hidden tradeoffs and complexities behind these sweeping pricing agreements: 🔗 https://sharxplan.com/news/a-hidden-tradeoff-in-trumps-mfn-drug-deals/

09/22/2026

High demand and steep price tags have made GLP-1 medications a massive financial strain for employer health plans. But navigating the economics of these blockbuster drugs involves much more than surface-level sticker shock.

"When it comes to the economics of medications, it is really hard to point your finger at a rational cause," SHARx Co-founder Paul Pruitt noted. "The manufacturing processes aren't necessarily disclosed, so you can't look at that as a contributing factor in a meaningful way."

Read the article to learn more about the misconceptions surrounding GLP-1 pricing, utilization, and the real impact they have on employer benefit plans: https://sharxplan.com/news/what-most-people-get-wrong-about-glp-1-drugs-like-ozempic-wegovy-and-zepbound/

09/18/2026

'𝐎𝐧 𝐭𝐡𝐞 𝐑𝐚𝐝𝐚𝐫' | 30th Edition is live!

Healthcare costs keep increasing, but transparency alone isn’t the finish line.

This edition focuses on:
• Why PBM reform may not automatically lower employer costs
• The growing opportunity for biosimilars
• Why having health insurance doesn’t always mean care is affordable
• New PBM rules increasing plan sponsor responsibility
• How patent strategies can delay lower-cost competition

Employers need to look beyond rebates and headline discounts to understand total pharmacy spend, incentive alignment, and the true financial impact on their plans.

Check out the thirtieth edition: 🔗 https://sharxplan.com/on-the-radar-30th-edition/

09/16/2026

Political debates over cancer drug prices often miss the hidden specialty pharmacy gatekeepers that dictate whether patients actually receive life-saving treatments.

"The future of oncology will undoubtedly include more sophisticated therapies, more personalized treatment strategies, and continued scientific breakthroughs," writes SHARx Chief Growth Officer, Paul Pruitt. "What remains uncertain is whether the systems surrounding those therapies will evolve at the same pace."

Read the article to learn how PBM vertical integration and complex administrative hurdles are shaping modern cancer care: 🔗 https://sharxplan.com/news/the-hidden-oncology-gatekeepers-shaping-access-to-life-saving-cancer-therapies/

09/14/2026

Major employers are cutting 2027 health benefits to curb rising healthcare expenses, leaving workers to assume higher premiums and reduced coverage. However, simply passing costs onto employees fails to fix the root issue, especially when it comes to skyrocketing prescription costs.

As pharmacy expenses continue to outpace medical trends, companies must rethink how they handle high-cost specialty drugs. Pointing toward alternative strategies, Paul Pruitt, Co-founder of SHARx, notes that employers need a new approach, "and maybe that's 'exiting the traditional insurance game.'"

Read the full article on USA TODAY to get all the details on upcoming benefit changes: https://sharxplan.com/news/major-companies-to-cut-back-on-2027-health-benefits-in-blow-to-workers/

09/07/2026

Today, we celebrate the dedication, talent, and tireless energy our employees bring to everything they do. Their hard work truly makes all the difference, and we are deeply grateful for the impact.

09/04/2026

What happens when a prescription costs more than a family can manage?

For Paul Pruitt, this is personal. In a recent news interview, SHARx’s Co-Founder and Chief Growth Officer shares his family’s experience navigating the cost of medications for his two sons, who live with a rare genetic disease.

The conversation highlights the growing pressure prescription drug costs place on families and employers, and why a better approach to prescription benefits is needed.

Watch the full interview: 🔗

In this segment featured on CBS’ 8 NewsNow, SHARx Co-Founder and Chief Growth Officer Paul Pruitt discusses the growing burden of prescription drug costs, drawing on both his professional experience and his family’s personal experience with a rare genetic disease. The conversation explores the c...